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Obesity and type 2 diabetes (T2D) are associated with chronic low-grade inflammation.
Mounting evidence suggests the involvement of an inflammatory switch in adipose tis-
sue, both in mature adipocytes and immune-competent cells from the stromal vascular
compartment, in the progression of obesity and insulin resistance. Several inflammatory
cytokines secreted by obese adipose tissue, includingTNFα and IL-6 have been described as
hallmark molecules involved in this process, impairing insulin signaling in insulin-responsive
organs. An increasing number of new molecules affecting the local and systemic inflam-
matory imbalance in obesity andT2D have been identified. In this complex condition, some
molecules may exhibit opposing actions, depending on the cell type and on systemic or
local influences. Tumor necrosis factor weak inducer of apoptosis (TWEAK), a cytokine of
the tumor necrosis (TNF) superfamily, is gaining attention as an important player in chronic
inflammatory diseases.TWEAK can exist as a full-length membrane-associated (mTWEAK)
form and as a soluble (sTWEAK) form and, by acting through its cognate receptor Fn14, can
control many cellular activities including proliferation, migration, differentiation, apoptosis,
angiogenesis, and inflammation. Notably, sTWEAK has been proposed as a biomarker of
cardiovascular diseases. Here, we will review the recent findings relating to TWEAK and
its receptor within the context of obesity and the associated disorder T2D.
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INTRODUCTION
A characteristic feature of obesity is a low-grade level of inflam-
mation, likely originating in the expanding adipose tissue, which is
illustrated by infiltration of immune cells, including macrophages,
lymphocytes, and leukocytes (1). Pro-inflammatory cytokines
released by activated immune cells and adipocytes can impair
insulin signaling in insulin-responsive organs, promoting systemic
insulin resistance, which increases the risk of developing type 2
diabetes (T2D) (2).
Tumor necrosis factor alpha (TNFα) was the first described
cytokine to have a relevant role in obesity and an associated
insulin-resistant state. Studies first conducted by Hotamisligil et al.
(3), demonstrated an upregulation of TNFα in adipose tissue from
obese patients. Since then, many members of the TNF superfamily
have been shown to participate in obesity related diseases, includ-
ing TNF-related apoptosis inducing ligand (TRAIL) (4), B cell
activating factor (BAFF) (5), Lymphotoxin-α (LTα) (6, 7), Lym-
photoxin β receptor (LTβR) (8), and Tumor necrosis factor ligand
superfamily member 14 (TNFSF14) (9) among others. Recently,
Abbreviations: BMI, body mass index; CD163, cluster of differentiation 163;
CVDs, cardiovascular disease; ERK, extracellular signal-regulated kinases; Fn14,
fibroblast growth factor-inducible 14; HOMA-IR, homeostasis model assessment of
insulin resistance; IL-6, interleukin 6; MAPKs, mitogen-activated protein kinases;
mTWEAK, full-length TWEAK isoform; NF-κB, nuclear factor kappa-light-chain-
enhancer of activated B cells; p38, mitogen-activated protein kinase; PP2A, protein
phosphatase 2A; sTWEAK, soluble TWEAK isoform; SVF, stromal vascular frac-
tion; T2D, type 2 diabetes; TNFα, tumor necrosis factor alpha; TRAF2, TNF
receptor-associated factor 2; TWEAK, tumor necrosis factor weak inducer of
apoptosis.
Tumor Necrosis Factor Weak Inducer of Apoptosis (TWEAK)
has gained attention as a potentially important regulator of the
inflammatory/anti-inflammatory equilibrium which takes place
in the insulin-resistant milieu. TWEAK is a cytokine belonging to
the TNF superfamily and triggers multiple, and often seemingly
conflicting, cellular activities in a wide variety of cells, ranging
from proliferation to cell death (10, 11). Like most TNF mem-
bers, TWEAK protein exists as a membrane-bound (mTWEAK)
form, and also as a soluble variant (sTWEAK), formed after prote-
olytic cleavage by a furin endoproteinase. Both forms are biolog-
ically active and can bind to Fibroblast growth factor-inducible
14 (Fn14), its only bona fide signal transducing receptor (12).
Studies in vitro suggests that mTWEAK, can function as a jux-
tacrine signaling molecule and sTWEAK can elicit qualitatively
different states of activity through Fn14 (12–14). Moreover, some
authors have proposed sTWEAK as a potential biomarker in
human cardiovascular diseases (CVDs) (15).
The cytoplasmic domain of Fn14 contains a TNF Receptor-
Associated Factor (TRAF) binding site allowing recruitment of
TRAF adapter proteins. This interaction is shared by most mem-
bers of the TNF receptor family including TNFα, and plays
a pivotal role in activating the nuclear factor κB (NF-κB) or
mitogen-activated protein kinase (MAPK) pathway, which can be
also activated by TWEAK (16). In particular, TRAF2 is impli-
cated in the activation of TWEAK signaling in several human cell
lines (17).
Interestingly, new data from human studies points to the
TWEAK/Fn14 axis as a component of the network that
contributes to the inflammatory imbalance occurring in insulin
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resistance-associated diseases (18–22). Here we review the role
of TWEAK in adipocyte biology, and the prognostic and diag-
nostic value of its soluble form sTWEAK, within the context of
insulin-resistant associated diseases, obesity, and diabetes.
TWEAK AND ADIPOCYTE BIOLOGY
Tumor necrosis factor weak inducer of apoptosis mRNA expres-
sion was initially described in multiple human tissues (23). How-
ever, the first data concerning the expression of this cytokine in
adipose tissue revealed mRNA gene expression of both TWEAK
and its receptor Fn14 in human fat depots from subcutaneous
and visceral origin (18, 19, 24). Furthermore, altered patterns
of TWEAK and Fn14 protein expression were observed in sub-
cutaneous adipose samples from severely obese subjects when
compared to healthy subjects (21).
In addition to adipocytes, adipose tissue contains a heteroge-
neous population of cells including preadipocytes, mesenchymal
stem cells (MSC), endothelial cells, and macrophages among oth-
ers cell types (25). Together, this collection of cells is termed
the stromal vascular fraction (SVF). From this compartment,
TWEAK expression has been detected mainly on the surface of
macrophages and lymphoid cells (21, 26), whereas Fn14 expres-
sion has been detected in mature adipocytes (18, 21, 27, 28),
preadipocytes (28, 29), MSC (29), and endothelial cells (30).
It is well recognized that Fn14 is a highly inducible recep-
tor (11). Inflammation can regulate the expression of Fn14 in
adipocytes and TWEAK in macrophages (19). In agreement
with this data, isolated adipocytes from severely obese sub-
jects exposed to a striking inflammatory environment, displayed
increased levels of Fn14 (18, 21). Independently of inflamma-
tion, hypoxic stress is suggested to be a contributing factor in
the adipocyte metabolism in the setting of obesity (31). Insuf-
ficient oxygen supply can lead to endoplasmic reticulum (ER)
stress and mitochondrial dysfunction, and hypoxia alters the bal-
ance between pro- and anti-inflammatory activities in adipose
tissue (32, 33). Although an up-regulation of the TWEAK/Fn14
axis, in parallel with hypoxia and ER-specific genes has been
observed in the adipose tissue of severely obese subjects, stud-
ies emulating hypoxia and ER stress in vitro do not report any
change in TWEAK/Fn14 gene expression in isolated adipocytes or
macrophages (19).
The pro-inflammatory milieu facilitated by hypoxia in adi-
pose tissue may represent an important stimulus for macrophage
attraction (34, 35). These cells may have a different polarized
state (termed M1 for the pro-inflammatory and M2 for the
anti-inflammatory subtypes) (35). Although there is a contro-
versy regarding the balance between M1 and M2 macrophages
in human obesity, and in obese mice models (36), many authors
agree that the M2 type constitute the most abundant infiltrating
macrophages found in human obesity (37, 38). In SVF from obese
subjects mTWEAK protein has been found over-expressed. Since
macrophages are an important component of the SVF cells, this
finding points to macrophages as one of the cells that expresses
this cytokine in the adipose tissue of obese subjects. In this regard,
in vitro studies describe a higher level of mTWEAK expression
in M2 human monocyte derived-macrophages when compared to
M1 cells (21).
Tumor necrosis factor weak inducer of apoptosis stimulus
may induce a pro-inflammatory activity in several human cell
types including endothelial, kidney, synoviocytes, and muscle cells,
among others (11). In human adipocytes, TWEAK stimulus alone
resulted in a modest pro-inflammatory state, with up-regulation
of the cytokines IL-6 and MCP-1, whereas leptin and adiponectin
expression were unaltered (19, 28). This inflammatory effect
seemed to be mediated through both canonical and non-canonical
NF-κB pathway activation. Whereas the canonical pathway was
activated in subcutaneous adipocytes, the non-canonical pathway
appeared activated only in visceral adipocytes (21, 22). Further-
more, a moderate induction of the MAPKs ERK1/2 and p38 after
TWEAK stimulus, has also been observed in both subcutaneous
and visceral adipocytes (19, 22).
It is known that TWEAK can interfere with the differentiation
ability of several cell types, including myogenic, osteoblast, chon-
drocyte, and erythroblast lineages (11). In addition, TWEAK can
also inhibit adipocyte differentiation at an early stage, as indicated
by a rapid reduction of the key adipogenic transcription factors
Peroxisome proliferator-activated receptor gamma (PPARγ) and
CCAAT/Enhancer Binding Protein α (C/EBPα) (28, 39).
In contrast to its effects on the differentiation capacity of
adipocytes, TWEAK does not influence the metabolic function
of these cells, such as glucose uptake and lipolysis. Furthermore,
distinct from its clear apoptotic effect in neurons, monocytes, and
tumor cell lines (40),a TWEAK stimulus does not induce apoptosis
in adipocytes (22, 28).
Overall, the main impact of TWEAK on adipocytes appears to
be an inhibition of adipocyte differentiation and the induction of
a moderate inflammatory response.
CIRCULATING LEVELS OF sTWEAK IN OBESITY AND
DIABETES
Diabesity is a new term coined to describe the common clin-
ical associations between obesity and T2D, and highlights the
close relationship between both states and their shared patho-
physiological mechanisms. Chronic and subtle inflammation is
usually documented in both states and can markedly influence
cardiovascular (CV) outcomes (41).
Since the observation of lower levels of sTWEAK in patients
with atherosclerosis and a negatively correlation between circu-
lating sTWEAK levels and the intima/media thickness in asymp-
tomatic subjects (15), decreased sTWEAK levels have been con-
firmed in many other CVD indications (40, 42–51). Consistent
with these findings, obese individuals also present a similar trend
of decreased sTWEAK in peripheral blood (21). Reinforcing the
hypothesis that low sTWEAK levels associate with a poor CV pro-
file, circulating levels of sTWEAK have also been found negatively
associated with levels of glucose, glycated hemoglobin (HbA1),
and also insulin resistance index (HOAM-IR) and central obe-
sity; all of which are well known CV risk factors (20, 21, 46, 52).
In contrast, the atherogenic lipid profile does not show a clear
inverse association with circulating sTWEAK, and opposing data
are reported in the literature. Whereas some studies describe a
negative relationship with total cholesterol and triglycerides in
severe obesity (21), other authors describe either a positive rela-
tionship with triglycerides (53) or no association at all (45). In
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severe obesity, changes in the levels of Free Fatty Acids were
found to negatively influence circulating sTWEAK, indicating that
lipotoxicity could be a modulator of sTWEAK levels. The obser-
vation of a lower rate of release of sTWEAK in carotid atheroma
plaques, compared to normal arteries, supports a link between
the lipotoxic effects of abnormal lipid accumulation and TWEAK
synthesis (15).
Some of the evidence mentioned may lead to speculation about
the potential anti-inflammatory behavior of sTWEAK, at least
in high-risk atherogenic conditions. Indeed, the inverse relation-
ship with inflammatory markers or surrogate inflammatory scores
lends support to this hypothesis (20, 53). The rise of circulating
sTWEAK levels after massive weight loss in severely obese sub-
jects reinforces the parallelism between expression of this cytokine
and other well recognized anti-inflammatory molecules such as
adiponectin (21). Along similar lines, a trend toward positive cor-
relation between levels of sTWEAK and adiponectin in patients
on chronic hemodialysis has been reported (52).
Recently, a new study highlighted the relevance of decreased
serum sTWEAK as a predictive marker of T2D. Interestingly this
study was conducted in a high CV risk population, in which the
incidence of T2D was assessed during a follow up (54). In this
large prospective nested case-control study lower sTWEAK serum
levels were found in incident cases compared to matched controls.
Indeed, previous cross-sectional studies have also proposed a link
between sTWEAK concentration and T2D (52).
The rationale that low levels of sTWEAK, in contrast to other
cytokines, appears as protective in conditions with high CV risk
diseases associated with an increased of chronic inflammatory
activity, is incompletely understood. Several conceivable explana-
tions have been proposed. A reduction of sTWEAK in serum, due
to uptake by the Fn14 receptor has been postulated. Endothelial
dysfunction is the initial pathophysiological step in the progres-
sion of vascular damage that precedes and leads to clinically visible
CVD (55). Under these conditions, Fn14 expression is increased
in the endothelium. Recently, we reported increased Fn14 expres-
sion in human adipocytes from severely obese subjects. These cells
also showed an increase in Fn14 expression after inflammatory
stimulation, thus increasing the availability for sTWEAK ligand,
which could lead to a peripheral reduction of serum sTWEAK
(19, 21).
An alternative hypothesis proposes the involvement of CD163,
a monocyte-macrophage surface receptor which has been sug-
gested to act as a scavenger receptor for sTWEAK (56). Sol-
uble CD163 (sCD163) is a macrophage-specific serum marker
which is elevated in inflammatory conditions (57). Circulat-
ing levels of sCD163 and sTWEAK are expressed in an oppo-
site trend in human carotid atherosclerotic plaques (58). More-
over, CD163-expressing macrophages can bind and internalize
sTWEAK in vitro (58). Thus, the reduction of sTWEAK could
be related to the presence of sCD163, which is up-regulated
both in patients with chronic kidney disease (CKD), and in
obese subjects (51, 59–61). This incremental increase could
enable sTWEAK degradation by inflammatory macrophages, lead-
ing to decreased sTWEAK levels, represented by the reduc-
tion in the sTWEAK/sCD163 ratio observed in some diseases
such CKD (51). Thus, low sTWEAK levels may be related to
the degree of macrophage activation. However, these observa-
tions are not fully coincident in TD2 patients. High serum
levels of sCD163 have been reported as a useful predictive
biomarker of T2D (62), but a more recent study reveals
no association between circulating sCD163 and the incidence
of T2D (54).
In contrast to the hypothesis of the potential anti-inflammatory
behavior of sTWEAK, animal studies with different approaches to
investigate the role of TWEAK/Fn14 axis in the development and
progression of atherosclerosis, gain of function, or loss of function,
have showed that TWEAK participates in the atherogenic process
(63, 64) indicating that the “net” effect of the pathway is damaging
rather than protective in this condition.
sTWEAK MODULATES TNFα ACTIVITY
To date, TNFα has focused the attention as a preponderant inflam-
matory cytokine with important implications both at local and
systemic levels in obesity and related diseases. The action of TNFα
on adipose tissue can alter the production of many adipokines, and
this is relevant for the systemic effects of TNFα on insulin sensitiv-
ity and whole body energy homeostasis (65). sTWEAK and TNFα
co-exist within the obese adipose tissue milieu, and both cytokines
have a pro-inflammatory potential, although at the same concen-
trations TNFα is a much more potent and rapid inflammatory
mediator than TWEAK (66).
Examination of the biological mechanisms through which
sTWEAK improves insulin sensitivity has demonstrated that, in
visceral adipocytes, treatment with sTWEAK ameliorates TNFα-
induced insulin resistance on glucose uptake. This occurs by abol-
ishing the stimulatory effect of TNFα on JNK1/2 kinase, which
is directly involved in the development of insulin resistance (67).
This effect is produced, at least in part, through a reduction in the
cellular concentration of TRAF2, leading to a curbing of TNFα
intracellular signaling events. Furthermore, this modulation of
TNFα-induced changes in insulin sensitivity was found to be asso-
ciated with an increase in the activity of PP2A, a Ser/Thr protein
phosphatase known to negatively regulate cytokine signaling (22).
Additionally, in human subcutaneous adipocytes, sTWEAK exerts
a modulator effect over TNFα-induced cytokine production by
inhibiting the MAPK and NF-κB signaling cascades commonly
used by TNFα (21).
This protective/modulatory effect of sTWEAK on TNFα activ-
ity has been observed in different cell types such cultured fibroblast
like synoviocytes obtained from synovial tissues of rheumatoid
arthritis patients (68), in mouse cerebral cortical neurons (69),
and also in several tumor human epithelial cell lines (70), suggest-
ing a broader and general competitive behavior between sTWEAK
and TNFα.
CONCLUDING REMARKS
The duality between inflammatory and anti-inflammatory activ-
ity seems to be one of the major elements in the evolution of high
CV risk diseases, such as obesity and T2D. In this scenario, some
molecules may display contradictory actions, depending on the
cell type and the location, and on the systemic, or local influence.
Here we have summarized emerging data on the role of
TWEAK within the context of metabolic inflammation. Despite
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FIGURE 1 | Model of the state of the art of TWEAK and TNFα
in obesity and T2D conditions. In obesity and T2D states, higher
circulating levels of TNFα and lower levels of sTWEAK have been
observed. Additionally, obese adipose tissue is highly infiltrated with
macrophages that could be a source of sTWEAK production and also
express mTWEAK on the surface. The latter may establish a strong
pro-inflammatory response in adipocytes where the Fn14 receptor is
over-expressed and activates the NF-κB pathway. In contrast, sTWEAK
has been identified as a negative regulator of TNFα signaling since both
signal via similar TNFR-associated factors, including TRAF2. Amelioration
of TNFα-induced insulin resistance by sTWEAK in obesity and T2D could
be a consequence, at least in part, of its direct regulation of JNK1/2
phosphorylation, controlled by PP2A phosphatase which is known to
negatively regulate cytokine signaling. PPA2 activation could thereby be
linked to the protective role of sTWEAK during the development of insulin
resistance. Thus it is tempting to speculate that in obesity and T2D, the
increase of mTWEAK and the decrease of sTWEAK may help to maintain
the pro-inflammatory effect of TNFα-driven response.
the moderate inflammatory activity of the sTWEAK cytokine
in adipocytes, a competitive interference ability of sTWEAK on
TNFα signaling in the adipocyte has been revealed. Contrary to
that observed with TNFα in obese and T2D patients, circulating
sTWEAK appears as a protective element under these conditions.
Interestingly, mTWEAK and sTWEAK have been shown to have
different effects on signal transduction pathways. Since mTWEAK
appears to be mainly expressed in macrophages, the metabolic
effects of TWEAK may therefore differ in cells having contact with
macrophages (e.g., adipocytes in an obesity context) and in more
distant cells living in a macrophage-free environment. Thus, it is
tempting to speculate that the decrease in sTWEAK levels, together
with an increase of mTWEAK, may help to maintain the local
pro-inflammatory effect of the TNF-α-driven response in obese
and T2D conditions (Figure 1). Hence, the use of recombinant
sTWEAK or Fn14 agonists to manipulate the TWEAK/Fn14 axis
offers an exciting perspective for the treatment of insulin resistance
and should be explored further.
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